163 related articles for article (PubMed ID: 24998574)
1. Functional RsaI/PstI polymorphism in cytochrome P450 2E1 contributes to bladder cancer susceptibility: evidence from a meta-analysis.
Deng XD; Gao Q; Zhang B; Zhang LX; Zhang W; Mu Er ZE; Xie Y; Ma Y; Liu Y
Asian Pac J Cancer Prev; 2014; 15(12):4977-82. PubMed ID: 24998574
[TBL] [Abstract][Full Text] [Related]
2. Functional PstI/RsaI polymorphism in CYP2E1 is associated with the development, progression and poor outcome of gastric cancer.
Feng J; Pan X; Yu J; Chen Z; Xu H; El-Rifai W; Zhang G; Xu Z
PLoS One; 2012; 7(9):e44478. PubMed ID: 22957075
[TBL] [Abstract][Full Text] [Related]
3. CYP2E1 RsaI/PstI polymorphism and gastric cancer susceptibility: meta-analyses based on 24 case-control studies.
Zhuo W; Zhang L; Wang Y; Ling J; Zhu B; Chen Z
PLoS One; 2012; 7(11):e48265. PubMed ID: 23139769
[TBL] [Abstract][Full Text] [Related]
4. CYP2E1 PstI/RsaI polymorphism and colorectal cancer risk: a meta-analysis.
Zhou GW; Hu J; Li Q
World J Gastroenterol; 2010 Jun; 16(23):2949-53. PubMed ID: 20556843
[TBL] [Abstract][Full Text] [Related]
5. CYP2E1 RsaI/PstI polymorphisms contributed to oral cancer susceptibility: a meta-analysis.
Guo Y; Zhou S; Liu F; Zhang B
Int J Clin Exp Pathol; 2015; 8(11):14685-92. PubMed ID: 26823792
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2E1 genotype in renal cell and urothelial cancer patients.
Farker K; Lehmann MH; Oelschlägel B; Haerting J; Hoffmann A; Janitzky V; Schubert J
Exp Toxicol Pathol; 1998 Sep; 50(4-6):425-31. PubMed ID: 9784018
[TBL] [Abstract][Full Text] [Related]
7. Does CYP2E1 RsaI/PstI polymorphism confer head and neck carcinoma susceptibility?: A meta-analysis based on 43 studies.
Zhuo X; Song J; Liao J; Zhou W; Ye H; Li Q; Xiang Z; Zhang X
Medicine (Baltimore); 2016 Oct; 95(43):e5156. PubMed ID: 27787372
[TBL] [Abstract][Full Text] [Related]
8. CYP2E1PstI/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility: A meta-analysis of the literature.
Boccia S; De Lauretis A; Gianfagna F; van Duijn CM; Ricciardi G
Carcinogenesis; 2007 Jan; 28(1):101-6. PubMed ID: 16837478
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2E1 RsaI/PstI polymorphism is associated with urologic cancer risk: evidence from a meta-analysis.
Lin YC; Wu X; Zhou XQ; Ren R; Su ZX; Liu CX
Int J Clin Exp Med; 2015; 8(6):8927-37. PubMed ID: 26309545
[TBL] [Abstract][Full Text] [Related]
10. The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case-control studies.
Tang K; Li Y; Zhang Z; Gu Y; Xiong Y; Feng G; He L; Qin S
BMC Cancer; 2010 Oct; 10():575. PubMed ID: 20969746
[TBL] [Abstract][Full Text] [Related]
11. CYP2E1 RsaI/PstI polymorphism and liver cancer risk among east Asians: a HuGE review and meta-analysis.
Tian Z; Li YL; Zhao L; Zhang CL
Asian Pac J Cancer Prev; 2012; 13(10):4915-21. PubMed ID: 23244081
[TBL] [Abstract][Full Text] [Related]
12. Updated meta-analysis of the association between CYP2E1 RsaI/PstI polymorphisms and lung cancer risk in Chinese population.
Wang YD; Yang HY; Liu J; Wang HY
Asian Pac J Cancer Prev; 2014; 15(13):5411-6. PubMed ID: 25040958
[TBL] [Abstract][Full Text] [Related]
13. Update meta-analysis of the CYP2E1 RsaI/PstI and DraI polymorphisms and risk of antituberculosis drug-induced hepatotoxicity: evidence from 26 studies.
Wang FJ; Wang Y; Niu T; Lu WX; Sandford AJ; He JQ
J Clin Pharm Ther; 2016 Jun; 41(3):334-40. PubMed ID: 27062377
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism in cytochrome P450 2E1 and alcoholic pancreatitis sus-ceptibility: a meta-analysis.
Wu C; Wu D; Liu Y; Zhong Y
Hippokratia; 2018; 22(2):60-67. PubMed ID: 31217677
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2E1 RsaI/PstI polymorphism and risk of esophageal cancer: A meta-analysis of 17 case-control studies.
Leng WD; Zeng XT; Chen YJ; Duan XL; Niu YM; Long RP; Luo ZX
Exp Ther Med; 2012 Nov; 4(5):938-948. PubMed ID: 23226753
[TBL] [Abstract][Full Text] [Related]
16. CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
Deng R; Yang T; Wang Y; Tang N
Int J Tuberc Lung Dis; 2012 Dec; 16(12):1574-81. PubMed ID: 23131254
[TBL] [Abstract][Full Text] [Related]
17. CYP2E1 genotyping in renal cell/urothelial cancer patients in comparison with control populations.
Farker K; Lehmann MH; Kästner R; Hoffmann A; Janitzky V; Schubert J; Matz U; Hofmann W
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):463-8. PubMed ID: 9760005
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of CYP2E1 5' regulatory RsaI/Pstl allelic variants and their role in risk for oral cancer.
Liu S; Park JY; Schantz SP; Stern JC; Lazarus P
Oral Oncol; 2001 Jul; 37(5):437-45. PubMed ID: 11377232
[TBL] [Abstract][Full Text] [Related]
19. CYP2E1 PstI/RsaI polymorphism and interaction with alcohol consumption in hepatocellular carcinoma susceptibility: evidence from 1,661 cases and 2,317 controls.
Liu C; Wang H; Pan C; Shen J; Liang Y
Tumour Biol; 2012 Aug; 33(4):979-84. PubMed ID: 22249978
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of cytochrome P450 2E1 RsaI/PstI and DraI polymorphisms in workers exposed to benzene].
Chen Z; Ling J; Liu Y; Wu X; Wang D; Wang J; Tu H
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2015 Aug; 33(8):595-7. PubMed ID: 26653810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]